MedTrace Logo

Phosphatidylserine, Taurine, and Caffeine for Cognitive Fatigue in Professional Football Players

NCT07696052 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-08-03

No results posted yet for this study

Summary

This randomized, double-blind, placebo-controlled, parallel-group trial will evaluate the effects of 28 days of taurine-caffeine supplementation with or without phosphatidylserine on neurocognitive fatigue resistance, visual search efficiency, and football-specific tactical decision-making in professional male football players. Sixty-two male outfield football players from two professional clubs will be randomized to placebo, taurine plus caffeine, or taurine plus caffeine plus phosphatidylserine. Laboratory and field-based outcomes will be assessed at baseline and after the supplementation period.

Conditions

  • Mental Fatigue
  • Cognitive Performance
  • Athletic Performance
  • Soccer Performance
  • Decision Making

Interventions

DIETARY_SUPPLEMENT

Placebo

Inert placebo matched with the active supplements for appearance, number of units, and packaging. The placebo will be administered for 28 days.

DIETARY_SUPPLEMENT

Taurine Plus Caffeine

Taurine 1500 mg/day plus caffeine 200 mg/day administered for 28 days. On training and testing days, the supplement will be consumed approximately 60 minutes before the main training session or testing procedure. On non-training days, it will be consumed at a consistent morning time.

DIETARY_SUPPLEMENT

Taurine, Caffeine, and Phosphatidylserine

Taurine 1500 mg/day plus caffeine 200 mg/day plus phosphatidylserine 600 mg/day administered for 28 days. On training and testing days, the supplement will be consumed approximately 60 minutes before the main training session or testing procedure. On non-training days, it will be consumed at a consistent morning time.

Sponsors & Collaborators

  • Józef Piłsudski University of Physical Education

    collaborator OTHER

  • Vizja University in Warsaw

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
37 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2026-08-31
Completion
2026-08-31

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07696052 on ClinicalTrials.gov